HumaninvsPinealamin

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Its discovery in 2001 was revolutionary — it was the first identified mitochondrial-derived peptide (MDP), challenging the long-held dogma that the mitochondrial genome only encodes 13 oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs. Humanin, along with MOTS-C and the SHLP peptides discovered later, established mitochondria as endocrine organelles.

Humanin exerts cytoprotective effects through multiple mechanisms. Extracellularly, it binds to a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha), and gp130 (the shared signaling subunit of the IL-6 receptor family). Activation of this complex triggers JAK/STAT3 signaling, which drives expression of anti-apoptotic genes (Bcl-2, Mcl-1) and cell survival programs. Intracellularly, humanin interacts directly with two pro-apoptotic proteins: it binds IGFBP-3, preventing IGFBP-3 from translocating to mitochondria and initiating apoptosis; and it binds BAX (Bcl-2-associated X protein), preventing BAX oligomerization and insertion into the outer mitochondrial membrane — the critical step in the intrinsic (mitochondrial) apoptosis pathway that releases cytochrome c and activates caspases.

Humanin also reduces cellular stress through multiple pathways. It decreases reactive oxygen species (ROS) production by optimizing mitochondrial electron transport chain function. It reduces endoplasmic reticulum (ER) stress by modulating the unfolded protein response (UPR). It improves insulin sensitivity through STAT3-mediated effects on hypothalamic signaling and peripheral insulin receptor substrate phosphorylation. Circulating humanin levels decline with age (approximately 40% reduction between youth and old age) and are inversely correlated with markers of age-related disease, suggesting that humanin decline contributes to the increased cellular vulnerability and apoptosis susceptibility seen in aging. Its most potent synthetic analogue, HNG (S14G-humanin), has a glycine-for-serine substitution at position 14 that increases cytoprotective potency approximately 1,000-fold.

Pinealamin is a low-molecular-weight peptide extract derived from the pineal glands of young cattle, processed to isolate short peptides (typically under 10 kDa) with proposed bioregulatory activity on pineal gland function. Unlike defined Khavinson tripeptides such as pinealon (Glu-Asp-Arg), pinealamin is a complex mixture of multiple peptide species, and its biological activity is attributed to the combined effect of these peptides rather than a single active component.

The proposed mechanism follows the Khavinson bioregulator framework: tissue-derived short peptides preferentially target the same tissue type from which they were extracted, binding to gene promoter regions and modulating expression of genes involved in pineal-specific functions. For pinealamin, this is hypothesised to include regulation of melatonin biosynthesis enzymes (notably AANAT and HIOMT), serotonin-to-melatonin conversion pathways, and the broader hypothalamic-pituitary-pineal axis that governs circadian rhythm.

Clinical positioning is primarily for age-related decline in melatonin secretion and associated sleep disorders in older adults — Russian observational studies have reported improvements in subjective sleep quality and measured melatonin output following pinealamin courses in middle-aged and elderly subjects. As with all Khavinson cytamins, the efficacy and mechanism evidence base sits almost entirely within Russian research traditions and has not been replicated in Western randomised controlled trials. The animal-derived sourcing also raises quality and safety considerations that vary significantly between suppliers, and pharmacopoeial standards for pinealamin do not exist outside Russian regulatory frameworks.